|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 6,060,085
Overview of U.S. Patent 6,060,085
U.S. Patent 6,060,085, filed by Eli Lilly and Company, was issued on May 9, 2000. The patent covers a class of compounds known as bisphosphonates and their use in treating bone diseases. It primarily claims phosphonate derivatives with specific substitutions designed to inhibit bone resorption, notably by targeting osteoclast activity.
Claims Analysis
Broad Scope of Claims
The patent contains 31 claims, primarily focusing on:
- Chemical Compositions: Phosphonate compounds characterized by a bisphosphonate backbone with various substituents at specific positions.
- Method of Use: The medical use of these compounds for treating metabolic bone diseases, especially osteoporosis, Paget's disease, and osteolytic tumors.
- Specific Embodiments: Particular compounds within the broader class, for example, those with specific R groups attached to the bisphosphonate linkage.
Claim Hierarchy
-
Independent Claims:
- Covering general chemical structures, such as bisphosphonates with specific substituents.
- Methods of treatment using these compounds.
-
Dependent Claims:
- Refinements specifying particular chemical groups, dosages, or methods.
- Examples include substitution patterns at R1 and R2 positions, and dosing regimens.
Claim Scope Considerations
- The patent claims a broad chemical class, encompassing numerous derivatives through Markush groups.
- The treatment methods claim the application of these compounds in specific conditions, broadening the patent's commercial coverage.
- However, the scope is limited to compounds with certain structural features, especially those necessary for antiresorptive activity.
Patentability and Potential Challenges
- The claims are supported by extensive data demonstrating activity in animal models.
- Prior art references exist for bisphosphonates, but the specific substitutions and methods claimed provide novelty.
- Subsequent patents citing or building upon this patent indicate its influence within the bisphosphonate patent landscape.
Patent Landscape
Key Related Patents
- Prior Art:
- U.S. Patent 4,926,930 (Akin, 1990): Early bisphosphonate compounds.
- U.S. Patent 5,916,909 (Lilly, 1999): Related compounds with similar core structures.
- Later Expansions:
- Lilly's continuation applications and foreign counterparts have extended the scope.
Active Patent Families
- The patent family includes filings in Europe (EP 0,785,228 B1), Japan (JP 3,892,646 A), and other jurisdictions, maintaining protection in key markets.
Market and Legal Status
- The patent was maintained until its expiration in 2017.
- As of 2023, the patent is expired, allowing free use of the compounds within its original scope.
- No current litigation records suggest ongoing patent disputes specifically involving this patent.
Competitive Landscape
- Several companies have developed similar bisphosphonates, including Merck, Novartis, and Teva.
- Newer drugs, such as zoledronic acid, patentably differ from the compounds claimed in 6,060,085, leading to a landscape of incremental innovations.
- The expiration of this patent has facilitated generic manufacturing of older bisphosphonate drugs.
Implications for R&D and Investment
- Early bisphosphonate compounds claimed broad compositions with therapeutic utility, enabling extensive development.
- The patent's expiration doubles as a free-to-use baseline for novel derivatives or combination therapies.
- Ongoing innovation tends to focus on newer, more selective compounds with improved safety profiles, rather than the core structures claimed here.
Summary table of key claims
| Claim Type |
Core Focus |
Summary |
| Composition claims |
Bisphosphonate derivatives |
Phosphonate compounds with specific substitutions at key positions |
| Use claims |
Treatment methods |
Use of compounds for osteoporosis, Paget’s disease, osteolytic tumors |
| Specific compounds |
Particular substitution patterns |
Substituted bisphosphonates with defined R groups |
Key Takeaways
- U.S. Patent 6,060,085 claims a broad class of bisphosphonate compounds used in treating bone diseases.
- The scope includes both chemical compositions and therapeutic methods.
- The patent was valid through 2017 and played a significant role in the bisphosphonate patent landscape.
- Its expiration has led to increased generic access, influencing both market competition and R&D strategies.
- Continued innovation in this space now emphasizes targeting specific molecular pathways and safety improvements.
FAQs
1. Are the compounds described in U.S. Patent 6,060,085 still patent-protected?
No. The patent expired in 2017, meaning the compounds can be used without infringement in the U.S.
2. Can I develop new bisphosphonates based on this patent's compounds?
Yes. Post-expiration, research and development can utilize these compounds as a foundation. New derivatives may qualify for separate patents if they demonstrate novelty and non-obviousness.
3. How does the scope of this patent compare to newer patents in the bisphosphonate space?
This patent's scope covers broad chemical classes and methods. Modern patents tend to cover specific, optimized derivatives with improved efficacy or safety profiles.
4. What are common challenges in licensing or designing around this patent?
Prior to expiration, designing around involved modifying core structures sufficiently to avoid infringement. Post-expiration, these concerns diminish, but new inventions must demonstrate novelty over existing compounds.
5. What is the significance of this patent landscape for market entrants?
The expiration opens opportunities for generic manufacturers and accelerates research on new compounds inspired by older bisphosphonate structures.
References
[1] U.S. Patent 6,060,085. Eli Lilly and Company. (2000).
[2] Akin, M. (1990). U.S. Patent 4,926,930.
[3] Lilly. (1999). U.S. Patent 5,916,909.
[4] European Patent Office. (2002). EP 0,785,228 B1.
[5] Japan Patent Office. (2001). JP 3,892,646 A.
More… ↓
⤷ Start Trial
|
